NCT05889572View on ClinicalTrials.gov

Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 8, 2023

Primary Completion Date

July 22, 2024

Study Completion Date

July 22, 2024

Conditions
Amyotrophic Lateral SclerosisALS
Interventions
DRUG

MaaT033

MaaT033 is a Microbiome Ecosystem Therapy (MET), composed of allogeneic, full-ecosystem pooled biotherapeutic gut microbiota.

Trial Locations (2)

59037

Centre Hospitalier Universitaire de Lille - CIC, Lille

75013

Hôpital de la Pitié-Salpêtrière - CIC Neuroscience, Paris

Sponsors

Lead Sponsor

MaaT Pharma
All Listed Sponsors
lead

MaaT Pharma

INDUSTRY